Literature DB >> 11036049

In vitro susceptibilities of Capnocytophaga isolates to beta-lactam antibiotics and beta-lactamase inhibitors.

A Jolivet-Gougeon1, A Buffet, C Dupuy, J L Sixou, M Bonnaure-Mallet, S David, M Cormier.   

Abstract

The susceptibilities of 43 pharyngeal isolates of Capnocytophaga to beta-lactam antibiotics, alone or in combination with beta-lactamase inhibitors, were tested by an agar dilution method. The 34 beta-lactamase-positive strains were highly resistant to beta-lactams, but the intrinsic activities of clavulanate, tazobactam, and sulbactam against Capnocytophaga, even beta-lactamase producers, indicates that these beta-lactamase inhibitors could be used for empirical treatment of neutropenic patients with oral sources of infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11036049      PMCID: PMC101629          DOI: 10.1128/AAC.44.11.3186-3188.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Beta-lactamase production by oral anaerobic gram-negative species in infants in relation to previous antimicrobial therapy.

Authors:  S Nyfors; E Könönen; A Takala; H Jousimies-Somer
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

2.  In vitro susceptibility of Capnocytophaga species to 29 antimicrobial agents.

Authors:  J L Rummens; B Gordts; H W Van Landuyt
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

3.  In vitro susceptibility of Capnocytophaga species to antimicrobial agents.

Authors:  P M Hawkey; S D Smith; J Haynes; H Malnick; S W Forlenza
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

4.  Capnocytophaga species: infections in nonimmunocompromised and immunocompromised hosts.

Authors:  D M Parenti; D R Snydman
Journal:  J Infect Dis       Date:  1985-01       Impact factor: 5.226

5.  Capnocytophaga sepsis: a newly recognised clinical entity in granulocytopenic patients.

Authors:  S W Forlenza; M G Newman; A I Lipsey; S E Siegel; U Blachman
Journal:  Lancet       Date:  1980-03-15       Impact factor: 79.321

6.  Antimicrobial susceptibility of Capnocytophaga.

Authors:  S W Forlenza; M G Newman; A L Horikoshi; U Blachman
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

7.  API ZYM system for identification of Bacteroides spp., Capnocytophaga spp., and spirochetes of oral origin.

Authors:  B E Laughon; S A Syed; W J Loesche
Journal:  J Clin Microbiol       Date:  1982-01       Impact factor: 5.948

8.  In vitro susceptibility of 96 Capnocytophaga strains, including a beta-lactamase producer, to new beta-lactam antibiotics and six quinolones.

Authors:  G Arlet; M J Sanson-Le Pors; I M Casin; M Ortenberg; Y Perol
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

9.  Selective recovery of oral Capnocytophaga spp. with sheep blood agar containing bacitracin and polymyxin B.

Authors:  P A Mashimo; Y Yamamoto; M Nakamura; J Slots
Journal:  J Clin Microbiol       Date:  1983-02       Impact factor: 5.948

10.  Enzymatic characterization of some oral and nonoral gram-negative bacteria with the API ZYM system.

Authors:  J Slots
Journal:  J Clin Microbiol       Date:  1981-09       Impact factor: 5.948

View more
  12 in total

1.  Genetic analysis of an ambler class A extended-spectrum beta-lactamase from Capnocytophaga ochracea.

Authors:  Anne Jolivet-Gougeon; Zohreh Tamanai-Shacoori; Laurent Desbordes; Nathalie Burggraeve; Michel Cormier; Martine Bonnaure-Mallet
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

2.  Molecular identification of Capnocytophaga spp. via 16S rRNA PCR-restriction fragment length polymorphism analysis.

Authors:  Marilou Ciantar; Hubert N Newman; Michael Wilson; David A Spratt
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

3.  'Bobo-Newton syndrome': An unwanted gift from man's best friend.

Authors:  Kristin Y Popiel; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

4.  Capnocytophaga canimorsus mycotic abdominal aortic aneurysm: why the mailman is afraid of dogs.

Authors:  David M Tierney; Leigh P Strauss; Jason L Sanchez
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

5.  Chromosome- and plasmid-encoded beta-lactamases in Capnocytophaga spp.

Authors:  Trude Handal; Chantal Giraud-Morin; Dominique A Caugant; Isabelle Madinier; Ingar Olsen; Thierry Fosse
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

6.  A Bite So Bad: Septic Shock Due to Capnocytophaga Canimorsus Following a Dog Bite.

Authors:  Michelle-Ashley Rizk; Nicholas Abourizk; Kinjal P Gadhiya; Panupong Hansrivijit; John D Goldman
Journal:  Cureus       Date:  2021-04-24

7.  Prevalence of oropharyngeal beta-lactamase-producing Capnocytophaga spp. in pediatric oncology patients over a ten-year period.

Authors:  Anne Jolivet-Gougeon; Zohreh Tamanai-Shacoori; Laurent Desbordes; Virginie Gandemer; Jean-Louis Sixou; Nolwenn Morvan-Graveline; Michel Cormier; Martine Bonnaure-Mallet
Journal:  BMC Infect Dis       Date:  2005-05-09       Impact factor: 3.090

8.  Infective endocarditis caused by Capnocytophaga canimorsus; a case report.

Authors:  Jun Sakai; Kazuhito Imanaka; Masahiro Kodana; Kana Ohgane; Susumu Sekine; Kei Yamamoto; Yusuke Nishida; Toru Kawamura; Takahiro Matsuoka; Shigefumi Maesaki; Hideaki Oka; Hideaki Ohno
Journal:  BMC Infect Dis       Date:  2019-11-04       Impact factor: 3.090

9.  Capnocytophaga canimorsus Bloodstream Infection Associated with an Urticarial Exanthem.

Authors:  John C Goetzinger; Austin L LaGrow; Dena R Shibib; Sharanjeet K Thind
Journal:  Case Rep Infect Dis       Date:  2021-06-10

10.  The Characteristics of Capnocytophaga Infection: 10 Years of Experience.

Authors:  Supavit Chesdachai; Don Bambino Geno Tai; Zachary A Yetmar; Anisha Misra; Natalie Ough; Omar Abu Saleh
Journal:  Open Forum Infect Dis       Date:  2021-04-15       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.